Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?

Company Performance - Gilead Sciences (GILD) shares have increased by 17.1% over the past month, reaching a new 52-week high of $117.39 [1] - The stock has gained 24.2% since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Biomedical and Genetics industry, both of which have seen a 6% return [1] Earnings and Revenue Expectations - Gilead has a strong record of positive earnings surprises, having met or exceeded earnings consensus estimates in the last four quarters [2] - For the current fiscal year, Gilead is expected to report earnings of $7.86 per share on revenues of $28.55 billion, reflecting a 70.13% change in EPS and a -0.7% change in revenues [3] - For the next fiscal year, earnings are projected to be $8.17 per share on revenues of $29.7 billion, indicating a year-over-year change of 3.9% in EPS and 4.01% in revenues [3] Valuation Metrics - Gilead's current valuation metrics show it trades at 14.6X current fiscal year EPS estimates, below the peer industry average of 19.3X [7] - On a trailing cash flow basis, Gilead trades at 16.7X compared to the peer group's average of 15.4X, with a PEG ratio of 0.75 [7] Zacks Rank and Style Scores - Gilead holds a Zacks Rank of 2 (Buy) due to rising earnings estimates, making it a suitable choice for investors [8] - The company has a Value Score of B, Growth Score of B, and Momentum Score of B, resulting in a combined VGM Score of A [6] Industry Comparison - The Medical - Biomedical and Genetics industry is performing well, ranking in the top 30% of all industries, providing favorable conditions for Gilead and its peers [11] - Jazz Pharmaceuticals PLC (JAZZ), a competitor, has a Zacks Rank of 1 (Strong Buy) and has shown strong earnings performance, with a projected EPS of $23.12 on revenues of $4.3 billion for the current fiscal year [9][10]